RMC-6291( —— )

Catalog No. M36627 CAS No. 2641998-63-0

RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models .

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	246	Get Quote
5MG	372	Get Quote
10MG	635	Get Quote
25MG	1086	Get Quote
50MG	1822	Get Quote
100MG	2907	Get Quote
500MG	Get Quote	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

RMC-6291
Note

Research use only, not for human use.
Brief Description

RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models .
Description

RMC-6291 is an orally active and covalent inhibitor of KRASG12C(ON). RMC-6291 forms a tri-complex within tumor cells between KRASG12C(ON) and cyclophilin A (CypA). Thus, RMC-6291 prevents KRASG12C(ON) from signaling via steric blockade of RAS effector binding. RMC-6291 elicits deep and durable suppression on RAS pathway activity in KRASG12C tumor models.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

Kras
Research Area

——
Indication

——

Chemical Information

CAS Number

2641998-63-0
Formula Weight

1012.26
Molecular Formula

C55H78FN9O8
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 100 mg/mL (98.79 mM; Ultrasonic )
SMILES

O=C(C#CC(N(C)C)(C)C)N1CCC(F)(C(=O)N(C)C(C(=O)NC2C(=O)N3NC(C(=O)OCC(C)(C)CC=4C5=CC(=CC=C5N(C4C=6C=CC=NC6C(OC)C)CC)N7CCOC(C7)C2)CCC3)C(C)C)CC1
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Nichols R J, et al. RMC-6291, a next-generation tri-complex KRASG12C (ON) inhibitor, outperforms KRASG12C (OFF) inhibitors in preclinical models of KRASG12C cancers[J]. Cancer Research, 2022, 82(12_Supplement): 3595-3595.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

Product			Quantity Required*
Name *			E-mail Address *
Organization *			Phone Number
Remarks